The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer
Open accessAbstract
Immune-checkpoint inhibitors (ICI) have transformed oncological therapy. Up to 20% of all non-small cell lung cancers (NSCLCs) show durable responses upon treatment with ICI, however, robust markers to predict therapy response are missing. Here we show that blood platelets interact with lung cancer cells and that PD-L1 protein is transferred from tumor cells to platelets in a fibronectin 1, integrin α5β1 and GPIbα-dependent manner. Platelets from NSCLC patients are found to express PD-L1 and platelet PD-L1 possess the ability to inhibit CD4 and CD8 T-cells. An algorithm is developed to calculate the activation independent adjusted PD-L1 payload of platelets (pPD-L1 Adj.), which is found to be superior in predicting the response towards ICI as compared to standard histological PD-L1 quantification on tumor biopsies. Our data suggest that platelet PD-L1 reflects the collective tumor PD-L1 expression, plays important roles in tumor immune evasion and overcomes limitations of histological quantification of often heterogeneous intratumoral PD-L1 expression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Thus, these results suggest that high-titer AAV disrupts the integrity of the BBB and enables components in circulating blood to enter the brain parenchyma.”
From High-titer AAV disrupts cerebrovascular integrity and induces lymphocyte infiltration in adult mouse brain (2023) · cites this paper as [38]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21654 · Cited by 16,522
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Cited by
Wu, M., Huang, Q., Xie, Y., Wu, X., Ma, H., Zhang, Y., & Xia, Y. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01242-2 · Cited by 456
The dynamic role of platelets in cancer progression and their therapeutic implications
Li, S., Lu, Z., Wu, S., Chu, T., Li, B., Qi, F., Zhao, Y., & Nie, G. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-023-00639-6 · Cited by 214
Zhao, M., Zhang, Y., Miao, J., Zhou, H., Jiang, Y., Zhang, Y., Miao, M., Chen, W., Xing, W., Li, Q., et al. (2023) · Advanced Materials · doi:10.1002/adma.202305243 · Cited by 130
Liao, K., Zhang, X., Liu, J., Teng, F., He, Y., Cheng, J., Yang, Q., Zhang, W., Xie, Y., Guo, D., et al. (2023) · MedComm · doi:10.1002/mco2.350 · Cited by 120
Zhang, X., Yu, S., Li, X., Wen, X., Liu, S., Zu, R., Ren, H., Li, T. X., Yang, C., & Luo, H. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106777 · Cited by 107
Metadata
- Authors
- Hinterleitner, C., Strähle, J., Malenke, E., Hinterleitner, M., Henning, M., Seehawer, M., Bilich, T., Heitmann, J., Lutz, M., Mattern, S., Scheuermann, S., Horger, M., Maurer, S., Walz, J., Fend, F., Handgretinger, R., Seitz, C., Weigelin, B., Singer, S., Salih, H., Borst, O., Kopp, H.-G., & Zender, L.
- Affiliations
- Universitätsklinikum Tübingen (DE)
- Memorial Sloan Kettering Cancer Center (US)
- University of Tübingen (DE)
- Robert Bosch Hospital (DE)
- German Cancer Research Center (DE)
- Corresponding author
- Zender, Lars
- ORCID
- Hinterleitner, Clemens
- Hinterleitner, Martina
- Seehawer, Marco
- Bilich, Tatjana
- Heitmann, Jonas
- Lutz, Martina
- Mattern, Sven
- Scheuermann, Sophia
- Horger, Marius
- Maurer, Stefanie
- Walz, Juliane
- Fend, Falko
- Handgretinger, Rupert
- Seitz, Christian
- Weigelin, Bettina
- Singer, Stephan
- Salih, Helmut
- Borst, Oliver
- Kopp, Hans-Georg
- Zender, Lars
- Venue
- Nature Communications
- Published
- 2021-12-01
- Volume
- 12
- Issue
- 1
- Pages
- 7005-7005
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC8636618
- OpenAlex
- W3215972122
- Cited by
- 175
- References
- 54
- Citations by year
- 2026: 26 · 2025: 45 · 2024: 43 · 2023: 44 · 2022: 17
- FWCI
- 9.56
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Deutsche Forschungsgemeinschaft (EXC2180, Project B05, SFB-TR240, EXC 2180—390 900 677, SFB/TR-209, 314905040, 267467939, FOR-2314, TR240, 390900677)
- Gottfried Wilhelm Leibniz Universität Hannover
- Deutschen Konsortium für Translationale Krebsforschung
- Leibniz-Gemeinschaft
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- non-small cell lung cancer, immune checkpoint inhibitors, immunotherapy response prediction, platelet-tumor cell interaction, FN1, alpha5beta1 integrin, GPIbα, tumor immune evasion, T cell suppression, platelet biomarkers
- MeSH terms
- Adult, Aged, Aged, 80 and over, Blood Platelets, Carcinoma, Non-Small-Cell Lung, Female, Humans, Immunologic Factors, Immunotherapy, Lung Neoplasms, Male, Middle Aged, T-Lymphocytes, Biomarkers, Tumor, Young Adult, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer. https://app.cochat.ai/papers/10.1038/s41467-021-27303-7
- The paper
- Hinterleitner, C., Strähle, J., Malenke, E., Hinterleitner, M., Henning, M., Seehawer, M., Bilich, T., Heitmann, J., Lutz, M., Mattern, S., Scheuermann, S., Horger, M., Maurer, S., Walz, J., Fend, F., Handgretinger, R., Seitz, C., Weigelin, B., Singer, S., . . . Zender, L. (2021). Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer. Nature Communications. https://doi.org/10.1038/s41467-021-27303-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.